Minerva Imaging ApS

Minerva Imaging ApS, based in Denmark, specializes in innovative oncology models and molecular imaging, offering essential services for translational cancer research and drug development, with a focus on targeted therapies. Minerva Imaging ApS operates as a Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), focusing on pre-clinical studies for oncology and cardiovascular diseases. Founded in 2011, the company has navigated the evolving landscape of cancer research while maintaining its headquarters in Denmark. The firm completed one significant funding round in June 2025, where Nordic Capital invested alongside the management team, although specific financial details were not disclosed.

Minerva Imaging offers a comprehensive suite of services as a CRO and CDMO, specializing in advanced oncology models and molecular imaging for translational cancer research and drug development. Their core offerings include pre-clinical study design and execution, with an emphasis on targeted radionuclide therapy within oncology. They also engage in cardiovascular disease research, serving clients in the pharmaceutical and biotechnology sectors. Their clientele includes research institutions and biotech firms across Europe, North America, and Asia, addressing critical scientific inquiries with tailored services.

Minerva Imaging generates revenue primarily through B2B transactions, engaging in partnerships with pharmaceutical and biotechnology companies. They provide specialized services that include the design and execution of pre-clinical studies and CMC/CDMO services that facilitate technology transfer to clinical applications. Their revenue in the most recent year was reported at an EBITDA of EUR 918,040. 60, demonstrating the firm’s commitment to customized project contracts that align with client needs.

In June 2025, Minerva Imaging secured an investment from Nordic Capital to strengthen its market presence and expand healthcare services. The company aims to enhance its offerings with new products focused on oncology and is considering expansion into additional geographic markets, including further outreach within North America and Asia. The investment will support these initiatives, reinforcing Minerva Imaging's commitment to addressing the growing demand for innovative cancer therapies and imaging technologies.